Can you now get a good deal on uniQure N.V’s shares?

While uniQure N.V has underperformed by -2.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, QURE rose by 181.71%, with highs and lows ranging from $19.18 to $3.73, whereas the simple moving average jumped by 32.46% in the last 200 days.

On April 01, 2025, Chardan Capital Markets started tracking uniQure N.V (NASDAQ: QURE) recommending Buy. A report published by Raymond James on December 10, 2024, Upgraded its rating to ‘Strong Buy’ for QURE. Raymond James also rated QURE shares as ‘Outperform’, setting a target price of $20 on the company’s shares in an initiating report dated October 10, 2024. Mizuho December 19, 2023d its ‘Buy’ rating to ‘Neutral’ for QURE, as published in its report on December 19, 2023. UBS’s report from March 17, 2022 suggests a price prediction of $40 for QURE shares, giving the stock a ‘Buy’ rating. BTIG Research also rated the stock as ‘Buy’.

Analysis of uniQure N.V (QURE)

Further, the quarter-over-quarter decrease in sales is -81.53%, showing a negative trend in the upcoming months.

There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of uniQure N.V’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -241.16% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.99, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

As an indicator of volatility for any stock, average volume can also be very valuable, and QURE is recording an average volume of 1.79M. On a monthly basis, the volatility of the stock is set at 3.51%, whereas on a weekly basis, it is put at 1.27%, with a loss of -9.49% over the past seven days. Furthermore, long-term investors anticipate a median target price of $35.50, showing growth from the present price of $14.79, which can serve as yet another indication of whether QURE is worth investing in or should be passed over.

How Do You Analyze uniQure N.V Shares?

Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.27%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.43% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

QURE shares are owned by institutional investors to the tune of 90.43% at present.

Hot this week

GDS Holdings Limited ADR (GDS) stock analysis: A simple moving average approach

While GDS Holdings Limited ADR has overperformed by 0.11%,...

Tronox Holdings plc (TROX)’s highs and lows: A closer look at its stock price fluctuations

While Tronox Holdings plc has overperformed by 0.18%, investors...

A year in review: Esperion Therapeutics Inc (ESPR)’s performance in the last year

While Esperion Therapeutics Inc has overperformed by 0.92%, investors...

TOI overperforms with a 1.71 increase in share price

While Oncology Institute Inc has overperformed by 1.71%, investors...

Technical analysis of Insmed Inc (INSM) stock chart patterns

While Insmed Inc has underperformed by -0.82%, investors are...

Topics

GDS Holdings Limited ADR (GDS) stock analysis: A simple moving average approach

While GDS Holdings Limited ADR has overperformed by 0.11%,...

Tronox Holdings plc (TROX)’s highs and lows: A closer look at its stock price fluctuations

While Tronox Holdings plc has overperformed by 0.18%, investors...

A year in review: Esperion Therapeutics Inc (ESPR)’s performance in the last year

While Esperion Therapeutics Inc has overperformed by 0.92%, investors...

TOI overperforms with a 1.71 increase in share price

While Oncology Institute Inc has overperformed by 1.71%, investors...

Technical analysis of Insmed Inc (INSM) stock chart patterns

While Insmed Inc has underperformed by -0.82%, investors are...

A stock that deserves closer examination: Perpetua Resources Corp (PPTA)

While Perpetua Resources Corp has overperformed by 2.68%, investors...

Perspective Therapeutics Inc (CATX) deserves deeper analysis

While Perspective Therapeutics Inc has underperformed by -2.27%, investors...

Was Foremost Clean Energy Ltd (FMST)’s session last reading good?

While Foremost Clean Energy Ltd has overperformed by 2.80%,...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.